Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes - (JAMA)
    TopAbstracts in Diabetes 11/25/2008 - (DGNews)
    Gene Variation in Diabetics Associated With Increased Risk of Coronary Artery Disease - (DGNews)
    Potassium Loss Caused by Thiazides May Explain Higher Risk of Adult Diabetes - (DGNews)
    Patients Taking Rosiglitazone Have Higher Risk of Death, Heart Failure Than Those Taking Pioglitazone - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
      Diabetes: Treatment of Type 2 Diabetes and the Role of Insulin
      Aggressive Management of Type 2 Diabetes to Prevent Macrovascular Complications
      MRSA And Diabetic Foot Wounds: Where Do We Go From Here?
      Type 2 Diabetes Across the Continuum of Care: Current Approaches for Glycemic Control in the Inpatient and Outpatient Setting
      Demystifying: Type 2 Diabetes Management

      Webcasts/CME archive

       Recent cases - Diabetes
        Vitamin D and Diabetes: Improvement of Glycemic Control with Vitamin D3 Repletion
        A Diabetic Patient Presenting with Stiff Hand Following Fasciectomy for Dupuytren's Contracture: A Case Report
        Burkholderia Pseudomallei Infection in a Patient with Diabetes Presenting with Multiple Splenic Abscesses and Abscess in the Foot: A Case Report
        HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
        Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Ezetimibe Plus Simvastatin Effective Treatment for Diabetics with Increased LDL-Cholesterol Levels: Presented at ADA

        By Jill Stein

        ORLANDO, FL -- June 7, 2004 -- Ezetimibe plus simvastatin helps diabetics achieve their target low-density lipoprotein (LDL) cholesterol levels more effectively than statins alone, researchers announced here on June 6th at the 64th Scientific Sessions of the American Diabetes Association (ADA).

        Ezetimibe inhibits intestinal absorption of both dietary and biliary cholesterol without affecting uptake of triglycerides or fat-soluble vitamins.

        James McKenney, MD, National Clinical Research, Inc., Richmond, Virginia, reported the results of a study that assessed whether ezetimibe co-administered with simvastatin would be more effective than simvastatin alone in helping diabetics achieve their LDL-cholesterol goals.

        "The incidence of coronary heart disease [CHD] among diabetic patients is two to four times that of nondiabetics," Dr. McKenney noted. Both the ADA and National Cholesterol Education Program (NCEP) guidelines recommend that diabetes be classified and managed as a coronary heart disease risk equivalent with a target LDL-cholesterol level of less than 100 mg/dL.

        "Statins are the drugs of choice to treat hypercholesterolemia in diabetic patients, however, many diabetics on statin therapy fail to reach their LDL-cholesterol target," he said.

        Roughly 700 participants in the present trial satisfied the NCEP criteria for CHD/CHD equivalent and had an LDL-cholesterol level that was 130 mg/dL or greater.

        Subjects were randomized to 23 weeks of daily treatment with simvastatin 20 mg, ezetimibe 10mg plus simvastatin 10 mg; ezetimibe 10mg plus simvastatin 20 mg; ezetimibe 10mg plus simvastatin 40 mg.

        Patients were evaluated for LDL levels at weeks 6, 12, and/or 18 and the simvastatin dose was doubled up to 80 mg in patients who did not reach target levels.

        The primary efficacy measure was the percentage of patients who reached their goal at 5 weeks.

        Results showed that more patients treated with combination therapy reached their LDL goal level (P <.001) than did patients treated with simvastatin alone at 23 weeks (P <.001). This was the case in both diabetics and nondiabetics. After controlling for baseline differences, goal attainment rates among diabetics and nondiabetics were not statistically different (P >.20).

        Ezetimibe plus simvastatin at any dose resulted in significantly greater percent decrease in LDL-cholesterol level than did simvastatin 20 mg alone. Patients treated with ezetimibe required fewer simvastatin dose titrations and used lower doses of simvastatin to achieve LDL-cholesterol levels less than 100 mg/dL than did patients on simvastatin alone.

        Diabetic patients tolerated the combination of ezetimibe and simvastatin and had favourable safety outcomes that were similar to those seen in nondiabetics.

        "Overall, the results show that therapy with ezetimibe/simvastatin coadministration -- a treatment strategy that provides dual inhibition of both the synthesis and intestinal absorption of cholesterol -- may help patients reach LDL-cholesterol goals with fewer titrations and using lower simvastatin doses," Dr. McKenney said.

        The study was sponsored by Merck/Schering-Plough Pharmaceuticals.


        [Presentation title: "LDL-Cholesterol Goal Attainment among Patients with Diabetes Mellitus Treated with Ezetimibe Plus Simvastatin Coadministration Versus Simvastatin



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send